Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
Times cited: 100
Abiraterone in metastatic prostate cancer without previous chemotherapy.
The New England journal of medicine.
Times cited: 917